# US 12,594,253 B2 · HIV inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,253 B2
- Document ID: US12594253B2
- Status: Granted
- Kind: B2
- Application number: 17/262,705
- Filed: 2019-07-24
- Published: 2021-08-19
- Granted: 2026-04-07
- Earliest claimed: 2018-07-25
- Assignees: Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V.
- Applicants: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Inventors: Marina V. Rodnina-Wintermeyer; Natalia Korniy; Ekaterina Samatova; Frank Peske
- Web page: https://patentgrep.com/patent/US12594253B2

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound comprising of the nucleotide sequence UAA or TAA and a binding site for the covalent attachment of leucine (Leu), wherein said compound is recognized by a ribosome, for use in medicine.

## Claims

### Claim 1

A method of treating or ameliorating an infection with HIV virus, with SIV virus, with an Alphavirus and/or AIDS in a subject, said method comprising administering a tRNALeu(UAA) which
(a) differs from any human wild-type tRNALeu(UAA), by at least one up to ten mutations of the base sequence in a stem region of the tRNA, wherein each of said mutations is a substitution or deletion; and/or
(b) comprises at least one modification of a ribose and/or of a phosphate, wherein said modification is selected from 2′-O-methyl, 2′-deoxy, 2′-fluoro, thiophosphate, LNA, and PNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tRNALeu(UAA), consists of the sequence of SEQ ID NO: 1 or 2.